Royalty Pharma Q2 adjusted EBITDA beats estimates

Royalty Pharma

05/08/2026 12:12

Overview
US biopharma royalty investor's Q2 Royalty Receipts grew 14%, Portfolio Receipts up 6% yr/yr
Adjusted EBITDA for Q2 beat analyst expectations
Company raised full-year 2026 guidance for Portfolio Receipts

Outlook
Royalty Pharma raises 2026 Portfolio Receipts guidance to $3.4 bln-$3.5 bln from $3.325 bln-$3.45 bln
Company expects 2026 Royalty Receipts growth of 7%-10%

Result Drivers
PRODUCT PERFORMANCE - Growth in Royalty Receipts was primarily driven by Tremfya, Voranigo, Imdelltra and Evrysdi
GENERIC COMPETITION - Declines from Promacta due to U.S. generic competition and from Imbruvica partially offset gains

Company press release: ID:nGNX5fkvP4

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Adjusted EBITDA
Beat
$736 mln
$670.61 mln (4 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Royalty Pharma PLC is $62.22, about 8.2% above its August 4 closing price of $57.48
The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 9 three months ago

Reuters Recommended Reads
Aug 4 - Pfizer Q2 results beat; raises 2026 revenue outlook
Aug 4 - Merck beats Q2 revenue estimates, raises FY revenue outlook
Aug 5 - Eli Lilly beats Q2 revenue estimates, raises FY revenue outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)